NYU Grossman School of Medicine New York, New York
Janus kinase (JAK) inhibitors are small molecule oral drugs approved for the treatment of moderate-to-severe ulcerative colitis in those have not responded or are intolerant to anti-TNF therapy. In this session, we will review the efficacy, use, and side effect profile of JAK inhibitors.
Learning Objectives:
Understand the efficacy of different JAK inhibitors
Understand the safety of JAK inhibitors, specifically herpes zoster infection and thromboembolism